Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Phase 2

Completed

Conditions: Relapsed Follicular Lymphoma

Interventions: Drug: rituximab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: VELCADE
Drug: prednisone

First Posted Date: 2008-07-15

Last Posted Date: 2013-04-29

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 55

Registration Number: NCT00715208

Locations: 🇺🇸
Loma Linda U Cancer Center, Loma Linda, California, United States
🇺🇸
Oklahoma Oncology and Hematology, PC, Tulsa, Oklahoma, United States
🇺🇸
Desert Hematology Medical Group, Inc., Rancho Mirage, California, United States

and more 39 locations

Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)

Phase 3

Completed

Conditions: Thrombotic Thrombocytopenic Purpura

Interventions: Drug: Cyclosporine
Drug: Prednisone

First Posted Date: 2008-07-11

Last Posted Date: 2023-05-03

Lead Sponsor: Ohio State University

Target Recruit Count: 26

Registration Number: NCT00713193

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX

Phase 2

Completed

Conditions: Liver Transplantation

Interventions: Drug: tacrolimus
Drug: Anti-IL2R AB
Drug: prednisone
Drug: Mycophenolate mofetil

First Posted Date: 2008-06-09

Last Posted Date: 2014-08-26

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 94

Registration Number: NCT00693524

Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma

Not Applicable

Conditions: Lymphoma

Interventions: Biological: rituximab
Biological: filgrastim
Biological: bleomycin sulfate
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisolone
Drug: vincristine sulfate
Drug: etoposide phosphate
Drug: methotrexate
Drug: cytarabine
Drug: ifosfamide
Drug: prednisone
Drug: vindesine

First Posted Date: 2008-06-04

Last Posted Date: 2009-07-08

Lead Sponsor: University Hospital Southampton NHS Foundation Trust

Target Recruit Count: 120

Registration Number: NCT00689845

Locations: 🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
🇬🇧
Christie Hospital, Manchester, England, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom

and more 5 locations

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2008-06-04

Last Posted Date: 2015-02-10

Lead Sponsor: Centre Antoine Lacassagne

Target Recruit Count: 30

Registration Number: NCT00690560

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, France

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: IMC-A12
Drug: Mitoxantrone
Drug: Prednisone
Biological: IMC-1121B (ramucirumab)

First Posted Date: 2008-05-23

Last Posted Date: 2014-10-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 138

Registration Number: NCT00683475

Locations: 🇺🇸
ImClone Investigational Site, Madison, Wisconsin, United States

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Phase 3

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: Placebo
Drug: Prednisone
Drug: sunitinib

First Posted Date: 2008-05-13

Last Posted Date: 2013-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 873

Registration Number: NCT00676650

Locations: 🇬🇧
Pfizer Investigational Site, Swansea, United Kingdom

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia
Childhood B Acute Lymphoblastic Leukemia

Interventions: Drug: Calaspargase Pegol-mknl
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Other: Pharmacological Study
Drug: Prednisone
Radiation: Radiation Therapy
Drug: Thioguanine
Drug: Vincristine Sulfate

First Posted Date: 2008-05-02

Last Posted Date: 2021-04-27

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 166

Registration Number: NCT00671034

Locations: 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
University of Connecticut, Farmington, Connecticut, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

and more 24 locations

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoma

First Posted Date: 2008-05-01

Last Posted Date: 2024-08-29

Lead Sponsor: Mayo Clinic

Target Recruit Count: 138

Registration Number: NCT00670358

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica

Phase 2

Completed

Conditions: Sciatica

Interventions: Drug: Placebo
Drug: Prednisone

First Posted Date: 2008-04-29

Last Posted Date: 2015-04-28

Lead Sponsor: Kaiser Permanente

Target Recruit Count: 269

Registration Number: NCT00668434

Locations: 🇺🇸
Kaiser Permanente, Roseville, California, United States
🇺🇸
Kaiser Permanente Northern California, Redwood City, Redwood City, California, United States
🇺🇸
Kaiser Permanente Northern California, San Jose, San Jose, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy